主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SEER
#3273
Seer, Inc. Class A Common Stock
1.7
2
-16.50%
版块:
基础:
利润货币:
日范围
年范围
日变化
-16.50%
每月变动
-9.47%
6个月变化
-16.50%
年变化
-20.74%
前一天收盘价
2.0
6
Open
1.7
2
Bid
Ask
Low
1.7
2
High
1.7
2
交易量
15
市场
股票
医疗保健
SEER
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Total assets
383.42 M
366.6 M
347.26 M
322.49 M
308.61 M
Total liabilities
38.7 M
39.03 M
36.26 M
34.2 M
36.79 M
Total equity
344.73 M
327.57 M
311.01 M
288.29 M
271.81 M
Total liabilities & shareholders' equities
383.42 M
366.6 M
347.26 M
322.49 M
308.61 M
Total debt
—
—
—
—
—
Net debt
—
—
—
—
—
Seer Inc - Class A
Seer, Inc. is an American biotechnology company headquartered in Redwood City, California. Established in 2017, the company develops technologies for proteomics research.
新闻
Seer, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:SEER) 2026-02-27
Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
Seer 2025年第四季度业绩:装机量激增67%,营收未达预期
Seer Q4 2025 slides: installed base surges 67%, revenue misses mark
Seer Q4 每股收益 超出预期, 营收 低于预期
Seer earnings beat by $0.02, revenue fell short of estimates
Seer将在美国HUPO会议上展示蛋白质组学技术
Seer to showcase proteomics technology at US HUPO conference
Mass spectrometry study validates protein-gene associations for drug discovery
Seer, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:SEER) 2025-11-26
Seer公司在CG医疗科技论坛:蛋白质组学创新引领潮流
Seer at CG MedTech Forum: Proteomics Innovations Lead the Way